top of page


NEW: Abstracts are now available to view via the program planner here.


The ISTH 2023 online program is now available to view. Begin planning your itinerary today!


Log in to the planner with your 4-digit or 5-digit registrant ID code (from your confirmation email) to save your favorite sessions. When we launch the ISTH 2023 app, your favorite sessions will transfer via your registrant ID. Lost your registrant ID? Email

New Planner Design

You may notice that the ISTH 2023 Congress planner and schedule looks a bit different this year. This year, the ISTH is offering CME (an optional purchase – learn more here) for our Plenary, State-of-the-Art and Oral Communication sessions. In accordance with our accreditation stipulations, these accredited sessions must be listed separately than our sessions that are not accredited. As such, you will see the following schedules within the ISTH 2023 program planner:

  • Accredited Sessions (offering CME credits): Plenary, State-of-the-Art, and Oral Communication Sessions

  • Unaccredited Sessions (do not offer CME credits): Career Development, Early Career, Master Classes, Nurses Forum, Poster Networking, Publication Only Abstracts, Publication Session and Scientific and Standardization Committee (SSC) sessions

  • Supported Sessions (do not offer CME credits): Presentation Theaters and Supported Symposia


Please get acquainted with these schedules before the meeting. Note: If you do not see full details for a session at this time, keep checking back, as the program continues to be updated.

The ISTH 2023 Congress Program will feature:

  • 4 plenaries 

  • 28 total State-of-the-Art sessions

  • 80 total oral communication sessions each featuring four presentations on the latest abstracts.

  • 24 Scientific and Standardization Committee (SSC) subcommittee sessions

  • 30 master classes and 12 career development sessions

  • Nurses Forum sessions 

  • Poster sessions

  • Supported symposia and presentation theaters 

  • Engaging industry exhibition 

After attending the ISTH 2023 Congress, learners will be able to do the following:

  • Describe coagulation mechanisms and how dysregulation of coagulation, including dysregulation associated with trauma, can lead to either bleeding or thrombosis.

  • Describe how bleeding is caused by protein deficiencies or defects in platelet function and how to treat such bleeding with either conventional therapies or newly developed therapeutics.

  • Compare how bleeding and thrombosis is different in children and adults.

  • Determine how thrombosis is caused by Sars-CoV-2 infection and how to effectively treat such thrombosis.

  • Describe how coagulation factors, platelets, and the vessel wall interact and how conditions such as advanced age, cancer, or pregnancy can alter these interactions to promote thrombosis.

  • Describe how treatments and new therapeutics will improve medical care for patients with either bleeding or thrombosis.


The ISTH 2023 Congress will feature four plenary sessions with these world-renowned speakers:

Dahlback Circle.png

Björn Dahlbäck
M.D., Ph.D.

akassoglou Circle.png

Katerina Akassoglou 

anand Circle.png

Sonia Anand
M.D., Ph.D.

libby Circle.png

Peter Libby

June 24| 17:00-17:30
A Life Spent Investigating Coagulation Factor V

Clive Kearon Memorial Lecture

June 25 | 09:30-10:15
Role of Fibrinogen in Neurodegenerative Disease

Alan Giles Memorial Lecture

June 26 | 9:30-10:15
Reducing the Burden of Peripheral Arterial Disease

Mary Patricia (Patti) Massicotte Memorial Lecture

June 27 | 9:30-10:15
Clonal Hematopoiesis in Thromboinflammation

 Paul Frenette Memorial Lecture

About the memorial lecture honorees:

  • Clive Kearon (1957 – 2020)
    Clive Kearon, M.D., Ph.D., was a world-renowned expert in venous thromboembolism, conducting clinical trials that informed clinical practice with respect to the diagnosis of venous thromboembolism, the duration and intensity of anticoagulant therapy for its treatment, and the role of thrombophilia testing. He was appointed chair of the highly cited guidelines for the treatment of venous thromboembolism published by the American College of Chest Physicians. Kearon served as Director for the Clinician Investigator Program at McMaster University for many years, mentoring the next generation of clinician-scientists.

  • Alan Randolph Giles (1940 – 2022)
    Alan R. Giles, M.D., established a highly innovative and productive hemostasis and thrombosis program at Queen’s University (Canada) including the second hemophilic dog colony in the world, which have been an invaluable asset for the development of novel hemophilia therapies, leading to major advances in recombinant Factor VIII therapy and the foundation for future ground-breaking gene therapy studies. Numerous aspiring clinicians and scientists from around the world would train in Alan’s lab over the years and become haemostasis and thrombosis leaders in their own right.

  • Mary Patricia (Patti) Massicotte (1955 – 2020)
    Patti Massicotte, M.D., was an active clinician-researcher, contributing significantly to the field of pediatric thrombosis and anticoagulation, including her role in the REVIVE and PROTEKT studies, which set the standard for randomized controlled trials of anticoagulation prevention and treatment strategies in children for nearly two decades. Through a collaboration, Massicotte also influenced warfarin management for children through her involvement with the EMPOWERMENT studies. She was passionate about mentoring and conducting research to improve clinical outcomes for children.

  • Paul Frenette (1965 – 2021)
    Paul Frenette, M.D., was a stalwart champion for medical research and for ensuring translation of his discoveries to the clinic for the benefit of patients with intractable medical conditions, including acute myeloid leukemia, prostate cancer, and sickle cell disease. His lab’s early work on selectins led to transformative treatments for vaso-occlusion in patients with sickle cell disease (SCD). He worked closely with physicians and drug companies to foster this finding into meaningful action, which culminated in the 2019 approval of an anti-P-selectin antibody for the treatment of SCD vaso-occlusion. Due to his attention to detail, Paul’s group made another unexpected seminal discovery that the nervous system regulated hematopoietic stem cell (HSC) behavior. This work thrust him to the forefront of the HSC niche field where he quickly became a rising star and leader.

bottom of page